跳至主要内容
临床试验/NL-OMON55572
NL-OMON55572已完成不适用

Detecting Subclinical Joint Bleeding and Inflammation in Haemophilia - BEGIN-study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 79 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
79

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Observational

入排标准

年龄范围
12 至 99(—)

入选标准

  • - Patient provides written, informed consent;
  • o Between January 1, 1970 and January 1, 1988 (METC 11-442)
  • o After January 1, 1988 and age >=16 years
  • - Severe haemophilia A (FVIII< 0.01 IU/ml)
  • - Treated at the Van Creveldkliniek, UMC Utrecht

排除标准

  • - History of inhibitor development (>= 5 Bethesda Units* (BU) at any time or 1-
  • 5 BU for >=1 year)
  • - Patients with a history of a major joint bleed in the three months prior to
  • - Patients with a history of a minor joint bleed in the month prior to
  • - MRI exclusion criteria, including MRI contraindications as per usual clinical
  • care, such as claustrophobia and metal or electronic implants not compatible
  • *One Bethesda unit (BU) is defined as that amount of inhibitor that results in
  • 50% re-sidual FVIII:C activity in tested plasma mixed with an equal volume of a
  • normal plasma pool (NPP) after incubation for 2 hours at 37°C.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验